The Latest Cardiac and Vascular News
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results. “Our results were driven by strong growth across key product lines, including the addition of new Cryo Nerve Block and Hybrid AF™ Therapy […]
RADIANCE-HTN TRIO and SOLO trial updates demonstrate the durability of blood pressure lowering effects of the Paradise Ultrasound Renal Denervation System in a broad spectrum of patients with hypertension. PALO ALTO, Calif.–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), a fully owned subsidiary of Otsuka Holdings Co., Ltd., and […]
Scipher to use proprietary patient molecular data analyzed by its SpectraTM platform to identify novel drug targets. TARA Biosystems to progress selected targets in its BiowireTM II drug discovery platform for cardiac laminopathies. Partnership set to reduce target discovery and validation from years down to months. NEW YORK & WALTHAM, […]
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”), a leading digital healthcare solutions company focused on the advancement of cardiac care, today commented on the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule. The Final […]
ENGLEWOOD, Colo., Nov. 2, 2021 /PRNewswire/ — 2021 Third Quarter Revenue increased 74% year over year to $34.8 million Orders increased 70% Record net income of $6.1 million; Diluted EPS $0.17 Adjusted EBITDA $9.3 million Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, […]
Olezarsen (IONIS-APOCIII-L Rx) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-L Rx) Phase 2 data to be presented at ACAAI Annual Meeting; Phase 3 initiation on track for year-end Tofersen Phase 3 VALOR study missed primary endpoint; signs of reduced disease progression observed across multiple secondary and […]
THOUSAND OAKS, Calif., Nov. 2, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2021. Key results include: Total revenues increased 4% to $6.7 billion in comparison to the third quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 4% globally, […]
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 3, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced its financial results for the quarter ended September 30, 2021. Total revenue in the third quarter of 2021 grew 17% year over […]
A unique new care management solution will accelerate diagnosis and treatment of AFib and sleep apnea patients in cardiology practices NEW YORK, Nov. 3, 2021 /PRNewswire/ — Peerbridge Health and BetterNight are partnering on a unique new care management solution designed specifically for cardiology practices for earlier identification, treatment, and optimization of […]
On-going Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for COVID-19 DSMC interim analysis of safety and efficacy data from ASPEN-COVID-19 completed with recommendation to continue trial to completion with no modifications Topline data anticipated in first quarter of 2022 Cash and cash equivalents of $58.3 million […]
